Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Mayo Clinic Arizona
Scottsdale, Arizona, United States
Univ Of Ark For Med Sci
Little Rock, Arkansas, United States
Agajanian Institute Of Hematology And Oncology
Downey, California, United States
Sharp Clinical Oncology Research
San Diego, California, United States
Va Ct Healthcare System
West Haven, Connecticut, United States
Medical Specialists Of Palm Beaches
Lake Worth, Florida, United States
James Graham Brown Cancer Center
Louisville, Kentucky, United States
3912 Taubman Center
Ann Arbor, Michigan, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Thomas Jefferson Univ.
Philadelphia, Pennsylvania, United States
Start Date
May 1, 2009
Primary Completion Date
June 1, 2012
Completion Date
September 1, 2013
Last Updated
October 17, 2016
1,714
ACTUAL participants
Brivanib
DRUG
Placebo
DRUG
Sorafenib
DRUG
Placebo
DRUG
Lead Sponsor
Bristol-Myers Squibb
NCT07267806
NCT07148310
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06812039